69245-79-0

Basic information

• Product Name: Phenol, 2-(4-morpholinylmethyl)-4-nitro-
• CAS NO: 69245-79-0
• Molecular Formula: C11H14N2O4
• Molecular Weight: 238.243
• Mol File: 69245-79-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Phenol, 2-(4-morpholinylmethyl)-4-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 2-(4-morpholinylmethyl)-4-nitro-(69245-79-0)
• EPA Substance Registry System: Phenol, 2-(4-morpholinylmethyl)-4-nitro-(69245-79-0)

Safety Data

• Hazardous Substances Data: 69245-79-0(Hazardous Substances Data)

Upstream product

• 100-02-7 4-nitro-phenol 
• 6050-58-4 4-morpholin-4-yl-butan-2-one 
• 34461-00-2 nitromalondialdehyde sodium salt 
• 110-91-8 morpholine 
• 50-00-0 formaldehyd 

Downstream Products

• 76226-59-0 4-amino-2-morpholinomethylphenol 
• 109-77-3 malononitrile 

Relevant articles and documents

Cathepsin B inhibitors: Further exploration of the nitroxoline core

Human cathepsin B is a cysteine protease with many house-keeping functions, such as intracellular proteolysis within lysosomes. Its increased activity and expression have been strongly associated with many pathological processes, including cancers. We present here the design and synthesis of novel derivatives of nitroxoline as inhibitors of cathepsin B. These were prepared either by omitting the pyridine part, or by modifying positions 2, 7, and 8 of nitroxoline. All compounds were evaluated for their ability to inhibit endopeptidase and exopeptidase activities of cathepsin B. For the most promising inhibitors, the ability to reduce extracellular and intracellular collagen IV degradation was determined, followed by their evaluation in cell-based in vitro models of tumor invasion. The presented data show that we have further defined the structural requirements for cathepsin B inhibition by nitroxoline derivatives and provided additional knowledge that could lead to non-peptidic compounds with usefulness against tumor progression.

Pyrazole compounds

Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

Synthesis of phenols and naphthol with n-morpholinomethyl pendants and their dimethylgallium complexes: Crystal structure of dimethylgallium-[4-nitro-2-(n-morpholinomethyl)-1-phenoxide]

The one-pot Mannich reaction was used to synthesize 2-(n-morpholinomethyl)-1-phenol (1a), 4-methyl-2-(n-morpholinomethyl)-1-phenol (1b), 4-chloro-2-(n-morpholinomethyl)-1-phenol (1c), 4-nitro-2-(n-morpholinomethyl)-1-phenol (1d), and 1-(n-morpholinomethyl)-naphthol (1e). The dimethylgallium complexes of these compounds have been prepared, and compound 2d has been determined by X-ray crystallography. The complex 2d crystallized with one unit having two identical molecules which have intermolecular contacts between the two phenyls caused by face to face π-π stacking. The Ga-O bond distances are noticeably shorter than in the other dimethylgallium phenoxides reported.